Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 9:13:5491-5508.
doi: 10.2147/CMAR.S312828. eCollection 2021.

Role of Systemic Inflammatory Reaction in Female Genital Organ Malignancies - State of the Art

Michal Mleko  1 , Kazimierz Pitynski  1 , Elzbieta Pluta  2 , Aleksandra Czerw  3   4 , Katarzyna Sygit  5 , Beata Karakiewicz  6 , Tomasz Banas  1
Affiliations
Review

Role of Systemic Inflammatory Reaction in Female Genital Organ Malignancies - State of the Art

Michal Mleko et al. Cancer Manag Res. .

Abstract

Systemic inflammatory reaction (SIR) is an unfavorable prognostic factor in many malignancies and has a role in all stages of the neoplastic process: initiation, promotion, and disease progression. Analysis of SIR can be performed by assessing indicators (eg, lymphocyte-to-neutrophil, platelet-to-lymphocyte, and monocyte-to-neutrophil ratios) and products of neutrophils and lymphocytes (ie, the systemic immune-inflammation index), or by examining the relationship between levels of C-reactive protein and albumin (based on the Glasgow Prognostic Score, modified Glasgow Prognostic Score, and C-reactive protein-to-albumin ratio). Risk stratification is essential in the clinical management of cancer; hence, the evaluation of these factors has potential applications in the clinical management of patients with cancer and in the development of new therapeutic targets. This review summarizes the current knowledge on SIR indicators and presents their clinical utility in malignancies of the female genital organs.

Keywords: C-reactive protein; breast cancer; cervical cancer; corpus uteri cancers; monocyte-to-lymphocyte ratio; neutrophil-to-lymphocyte ratio; platelet-to-lymphocyte ratio; systemic inflammatory reaction; vaginal cancer; vulvar cancer.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Association between elevated neutrophil-to-lymphocyte ratio (NRL), survivals and clinicopathological features in breast, endometrial, ovarian, cervical, vulvar and vaginal cancers.
Figure 2
Figure 2
Association between elevated platelet-to-lymphocyte ratio (PRL), survivals and clinicopathological features in breast, endometrial, ovarian, cervical, vulvar and vaginal cancers.
Figure 3
Figure 3
Association between elevated lymphocyte-to-monocyte ratio (LMR) survivals and clinicopathological features in breast, endometrial, ovarian and cervical cancers.
Figure 4
Figure 4
Association between elevated tumor-associated macrophages (TAMS) survivals and clinicopathological features in breast, endometrial, ovarian and cervical cancers.
See this image and copyright information in PMC

References

    1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991–998. doi:10.1038/ni1102-991 - DOI - PubMed
    1. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137–148. doi:10.1016/j.immuni.2004.07.017 - DOI - PubMed
    1. Zou W. Immunosupressive networks in the tumor environment and their therapeutic relevance. Nat Rev Cancer. 2005;5:247–263. doi:10.1038/nrc1586 - DOI - PubMed
    1. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006;66:5527–5536. doi:10.1158/0008-5472.CAN-05-4128 - DOI - PubMed
    1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–545. doi:10.1016/S0140-6736(00)04046-0 - DOI - PubMed